title: [Still questions around the slimming agent rimobant. Not approved in USA because of the risk of mental adverse effects].
authors.affiliation: Läkemedelscentrum, Stockholms.
authors.forename: Björn
authors.initials: B
authors.lastname: Wettermark
authors.forename: Pauline
authors.initials: P
authors.lastname: Raaschou
authors.forename: Tomas
authors.initials: T
authors.lastname: Forslund
authors.forename: Paul
authors.initials: P
authors.lastname: Hjemdahl
mesh_terms: D019440:Anti-Obesity Agents / Q000009:adverse effects*; D063387:Cannabinoid Receptor Antagonists; D003863:Depression / Q000139:chemically induced*; D017277:Drug Approval; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D010880:Piperidines / Q000009:adverse effects*; D011720:Pyrazoles / Q000009:adverse effects*; D000077285:Rimonabant; D012307:Risk Factors; D015431:Weight Loss / Q000187:drug effects
chemical_list: D019440:Anti-Obesity Agents; D063387:Cannabinoid Receptor Antagonists; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant